What is Malignant hyperthermia

Malignant hyperthermia is a rare, life-threatening pharmacogenetic disorder that causes a severe reaction to certain anesthetic drugs used during surgery. When exposed to these triggers, individuals with malignant hyperthermia experience a rapid, dangerous rise in body temperature and severe muscle contractions, requiring immediate medical intervention. Because it is an inherited condition, identifying susceptibility before anesthesia is critical for patient safety.

What happens to the body during a malignant hyperthermia episode?

The primary systems affected by malignant hyperthermia are the skeletal muscles and the metabolic system. Under normal conditions, calcium ions regulate muscle contraction. In individuals with this condition, exposure to volatile anesthetic gases (like sevoflurane or desflurane) or the muscle relaxant succinylcholine causes an uncontrolled release of calcium within the muscle cells. This leads to sustained muscle rigidity, an extreme increase in oxygen consumption, massive heat production, and the breakdown of muscle tissue (rhabdomyolysis). If left untreated, this metabolic crisis can lead to organ failure and cardiac arrest.

How common is malignant hyperthermia and who is at risk?

The prevalence of malignant hyperthermia is estimated to be between 1 in 5,000 and 1 in 50,000 exposures to triggering anesthetic agents. The condition does not typically manifest until the patient is exposed to a triggering drug, meaning many people may live their entire lives without knowing they carry the genetic predisposition. It affects both males and females equally, and while it can occur at any age, it is most frequently diagnosed in children and young adults during their first or early surgical experiences.

What causes this condition and how is it inherited?

Malignant hyperthermia is primarily caused by mutations in the RYR1 gene, which provides instructions for making the ryanodine receptor protein in muscle cells. This condition follows an autosomal dominant inheritance pattern, meaning a person only needs to inherit the genetic variant from one parent to be at risk. Key facts regarding the underlying mechanism include:

• Genetic Basis: Over 70% of clinical cases are linked to mutations in the RYR1 gene.


• Trigger Sensitivity: The disorder is not a constant state; it is a "latent" condition that only becomes active upon exposure to specific pharmacological agents.


• Clinical Variability: Because of the genetic complexity, the severity of a malignant hyperthermia reaction can vary significantly even among family members with the same mutation.

How is malignant hyperthermia different from other heat-related illnesses?

It is crucial to distinguish malignant hyperthermia from other hyperthermic conditions like heatstroke or neuroleptic malignant syndrome (NMS). Unlike heatstroke, which is caused by environmental factors, this condition is strictly triggered by anesthetics. Furthermore, while NMS shares some clinical features, it is associated with antipsychotic medications rather than volatile anesthetics. The 42 members currently in the DiseaseMaps.org community often emphasize the importance of sharing family surgical histories to help others identify these risks early.

Next steps

• Consult an Anesthesiologist: If you have a family history of unexplained surgical deaths or high fevers during anesthesia, inform your surgical team well in advance.


• Genetic Counseling: Speak with a clinical geneticist to discuss RYR1 testing options for you and your family members.


• Join the Community: Connect with the 42 individuals on DiseaseMaps.org who have experience navigating life with this diagnosis.


• Medical Alert Identification: Consider wearing a medical alert bracelet that identifies your susceptibility to anesthesia triggers.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Malignant hyperthermia overview.


• Orphanet: Malignant hyperthermia (ORPHA:423).


• Malignant Hyperthermia Association of the United States (MHAUS): Clinical guidelines and patient resources.


• OMIM (Online Mendelian Inheritance in Man): Malignant Hyperthermia, Susceptibility To; MHS (Entry #145600).